Ovarian cancer diagnostics market seen reaching $4.2 billion by 2030

The Business Research Company says the ovarian cancer diagnostics market is set to grow from $2.9 billion in 2025 to $3.11 billion in 2026, then climb to $4.2 billion by 2030. The outlook reflects rising cancer incidence, more early-screening efforts and growing use of AI, biomarkers and advanced imaging.

Why it matters: - Ovarian cancer diagnostics are becoming a bigger part of the women’s health market as providers and researchers push for earlier detection and more personalized treatment. - The market’s projected growth signals rising demand for tools that can improve diagnosis speed and accuracy, which can affect treatment outcomes.

What happened: - The Business Research Company released a market study on the ovarian cancer diagnostics sector on August 21, 2026. - The study says the market will rise from $2.9 billion in 2025 to $3.11 billion in 2026, a 7.4% compound annual growth rate. - The same study projects the market will reach $4.2 billion by 2030, at a 7.7% compound annual growth rate. - The report is available as a full market report. - A free sample report is also available.

The details: - The study says historical growth has been supported by rising ovarian cancer incidence, greater awareness of women’s health, expanded diagnostic laboratory infrastructure, more imaging and biopsy procedures, and cancer screening initiatives. - The report says future growth will be driven by precision oncology investment, stronger demand for early cancer detection, wider use of AI-powered diagnostic platforms, personalized treatment approaches and more funding for women’s cancer research. - The study identifies biomarker-based tests, advanced imaging, artificial intelligence in detection, expanded early screening programs and personalized oncology diagnostics as key forecast-period trends. - Ovarian cancer diagnostics include symptom review, physical exams and specialized diagnostic tests used to identify and confirm ovarian cancer. - Ovarian cancer is a malignant growth that starts in the ovaries, which are part of the female reproductive system. - The report says early and accurate diagnosis is essential for effective treatment and better patient outcomes. - Cancer Australia reported about 6,963 new cases of gynecological cancers in 2024, a data point the report uses to show the scale of demand for diagnostics. - The study says North America led the market in 2025. - The Asia-Pacific region is expected to grow fastest خلال the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, a company scoring matrix, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables.

Between the lines: - The report points to a market shift from broad cancer detection toward earlier, more precise and data-driven diagnosis. - AI and biomarker testing are moving from emerging tools to core growth themes, which suggests diagnostics vendors may need to compete on speed, accuracy and integration rather than only test volume. - North America’s lead and Asia-Pacific’s faster growth hint at a mature market in the U.S. and Canada, with more expansion room in faster-developing health systems.

What's next: - The market is likely to keep expanding as screening programs widen and oncology care becomes more personalized. - Adoption of AI-enabled and biomarker-based diagnostic platforms will be a key indicator to watch through 2030. - More research funding for women’s cancers could accelerate new test development and commercialization.

The bottom line: - Ovarian cancer diagnostics is a growing global market, and the next phase of growth appears tied to earlier detection, smarter testing and broader access to screening.